DDX3X is a poor prognostic marker in cohorts of liver cancer, pancreatic cancer, breast cancer, and ovarian cancer, while patients of colorectal cancer, urothelial cancer, lung cancer, and gastric cancer expressing high DDX3X level associate with better outcomes. This evidence concerns the gene DDX3X and familial pancreatic carcinoma.